Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yang Liu (NPI 1285079988)

Field	Value
Entity Type	Individual
Organization	Yang Liu
Address	1580 Beam Ave
City	Maplewood
State	MN
ZIP	55109
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 8, 2013

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This clinician is a hematology & oncology physician in Maplewood, MN with an NPI enumerated ~13 years ago (2013-05-08), indicating over a decade of Medicare billing history to evaluate. The tenure suggests an established practice footprint rather than a newly registered provider, which supports interpretation of multi-year service and referral patterns in the data.

Medicare is effectively the sole public payer recorded: total Medicare revenue is $1.4M while there is no Medicaid billing on file, so the provider functions as a single-payer (Medicare-centric) biller in the available dataset. This concentration implies analyses of patient mix, utilization, and reimbursement should focus on Medicare claims rather than Medicaid.

Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 68.7% of the provider's total Medicare revenue, meaning a small set of high-cost drug administrations dominate reimbursement. Those top codes—J9271, J9299, and Q5118—drive the majority of dollars and therefore represent the core service lines for this practice.

The code mix indicates the practice is centered on high-cost oncology drug administration and infusion services. Leading revenue comes from pembrolizumab (J9271), nivolumab (J9299), and a bevacizumab biosimilar (Q5118), complemented by supportive oncology drugs and chemotherapy administration codes (96413, 96375, 96417). This pattern is consistent with an infusion/oncology practice delivering checkpoint inhibitors and related therapies in the outpatient setting.

Competitive standing across specific Medicare codes is mixed: for pembrolizumab (J9271) the provider ranks #1157 of 1841 (36th percentile), reflecting typical, unremarkable national volume; for nivolumab (J9299) the provider ranks #224 of 505 (56th percentile), a modestly above-median presence; and for the bevacizumab biosimilar (Q5118) the provider ranks #31 of 161 (81st percentile), representing relatively high national volume for that specific biosimilar. Overall, the provider is not a dominant national player for the top checkpoint inhibitor J9271 but shows stronger relative activity for some biologic agents.

There are notable statistical outliers within the code mix that suggest particular operational emphases: J2506 (pegfilgrastim) ranks #34 of 586 (94th percentile) and is labeled notably above typical national volume, indicating an elevated use of growth-factor support; conversely J9171 (docetaxel) ranks #3 of 207 (99th percentile) and is flagged an extreme outlier, signaling an unusually large national volume for docetaxel claims relative to peers. These flagged positions highlight specific drugs where this provider’s utilization departs meaningfully from national norms.

Evaluation and management and supportive services are present but not primary revenue drivers: 99214 and 99213 appear in the top codes but together account for small shares of total Medicare revenue, consistent with a practice model where high-cost infused biologics and chemotherapy dominate billing. Imaging and advanced diagnostics (78815, A9552) also appear at low claim counts but with higher paid-per-claim amounts, reflecting episodic use of PET/CT and FDG study in the oncology workflow.

Operational implications: because nearly 69% of Medicare revenue is concentrated in three infusion/biologic codes, payer negotiation, drug acquisition and reimbursement policies for those agents (and biosimilars) will disproportionately affect the provider’s revenue profile. The absence of Medicaid billing means shifts in state programs or Medicaid-managed-care contracts are less likely to impact this provider based on available data.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

66 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,200	$40	$438.6K
J9299	Injection, nivolumab, 1 mg	16,000	$20	$384K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	4,310	$20	$99.1K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	970	$80	$74.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$110	$50.3K
J0897	Injection, denosumab, 1 mg	2,220	$20	$42.2K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	40	$1,200	$42.1K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	310	$130	$40.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	340	$90	$31.2K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	9,670	$1	$19.3K

Showing 1–10 of 66

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 66 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Yang Liu — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

66 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	70	7,200	$40	$323.3K
J9299	1	20	5,240	$20	$159.4K
J0897	35	90	1,770	$20	$50.8K
J2506	2	20	290	$80	$34.3K
Q5118	1	20	990	$20	$33.7K
78815	108	180	50	$250	$25.6K
J0881	10	20	10,680	$1	$25.4K
A9552	33	60	30	$370	$17.2K
J9217	8	80	80	$130	$17.1K
74177	801	890	130	$80	$13.7K

Showing 1–10 of 66

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yang Liu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Park Nicollet Clinic	MN	Family Medicine Physician	$0	$210M
Park Nicollet Methodist Hospital	MN	General Acute Care Hospital	$0	$17.2M
Holland Center	MN	Developmentally Disabled Services Day Training Agency	$0	$16.3M
Minnesota Oncology Hematology, PA	MN	Hematology & Oncology Physician	$0	$8.1M
Tria Orthopaedic Center LLC	MN	Orthopaedic Surgery Physician	$0	$7.3M
Baldwin Area Medical Center, Inc.	WI	Critical Access Hospital	$0	$3.1M
Robert Delaune	MN	Hematology & Oncology Physician	$1.9M	$0
Vladimir Hugec	MN	Hematology & Oncology Physician	$1.8M	$0
Mehdi Najafi	MA	Ophthalmology Physician	$1.8M	$0
Marni Feldmann	MN	Retina Specialist (Ophthalmology) Physician	$1.7M	$0

Nearby Providers

Other providers in the same ZIP code as Yang Liu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rem Ramsey, Inc.	MN	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$207.6M
Community Dental Care Inc	MN	General Practice Dentistry	$0	$30.7M
Senior Home Living Inc	MN	Personal Care Attendant	$0	$29.4M
Rainbow Home Healthcare Inc	MN	Home Health Agency	$0	$22.2M
Healtheast St. John's Hospital	MN	General Acute Care Hospital	$0	$17.9M
Cochran Recovery Services	MN	Substance Abuse Rehabilitation Facility	$0	$15.4M
Ardent Home Health Care Inc.	MN	Home Health Agency	$0	$12.2M
First Nations, LLC	MN	In Home Supportive Care Agency	$0	$11.3M
Hmong Minnesota Senior Center	MN	Adult Day Care Clinic/Center	$0	$10M
Healtheast Medical Research Institute	MN	Clinic/Center	$0	$7.4M

Yang Liu — Billing Profile & Reimbursement Data

Sign up for Yang Liu — Billing Profile & Reimbursement Data policy alerts

Yang Liu — Billing Profile & Reimbursement Data

Sign up for Yang Liu — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References